Project 170849
A Unifying Mechanism for the Anti-inflammatory Effect of Phosphodiesterase 4 Inhibitors in Chronic Obstructive Pulmonary Disease
A Unifying Mechanism for the Anti-inflammatory Effect of Phosphodiesterase 4 Inhibitors in Chronic Obstructive Pulmonary Disease
Project Information
| Study Type: | Other Mechanistic_Study |
| Therapeutic Area: | Respiratory |
| Research Theme: | Biomedical |
| Disease Area: | COPD, bronchitis, emphysema |
| Data Type: | Canadian |
Institution & Funding
| Principal Investigator(s): | Giembycz, Mark A |
| Institution: | University of Calgary |
| CIHR Institute: | Infection and Immunity |
| Program: | |
| Peer Review Committee: | Respiratory System |
| Competition Year: | 2008 |
| Term: | 5 yrs 0 mth |
Abstract Summary
Phosphodiesterase (PDE) 4 inhibitors are a new class of drugs being developed for the treatment of chronic obstructive pulmonary disease (COPD), which is more commonly referred to as bronchitis and/or emphysema. The results of several clinical trials in subjects with COPD suggest that PDE4 inhibitors can slow the development of this disease. Hoewever, exactly how this novel class of drugs do this has not been investigated and, accordingly, is not understood. Clearly, a complete appreciation of how PDE4 inhibitors work in COPD is a desirable objective if their effectiveness is to be optimized or, ideally, enhanced.
Research Characteristics
This project includes the following research characteristics:
Study Justification
"how this novel class of drugs do this has not been investigated and, accordingly, is not understood. Clearly, a complete appreciation of how PDE4 inhibitors work in COPD is a desirable objective"
Novelty Statement
"a complete appreciation of how PDE4 inhibitors work in COPD is a desirable objective if their effectiveness is to be optimized or, ideally, enhanced."
Methodology Innovation
investigating the unifying mechanism for anti-inflammatory effects of PDE4 inhibitors in COPD